More predictive in vitro assays may improve nanomedicine: Protein corona formation information exploited to optimize carriers for nanomedical applications

One recent obstacle to drug delivery research is an observed weak correlation between in vitro and in vivo performance. When nanoparticles are applied intravenously, they face several obstacles that differ from in vitro situations. Nanoparticles are usually covered by a biomolecular multilayer (a protein corona), which alters the physiochemical properties, pharmacokinetics, and toxicity profile of the nanoparticles.